More tools:Markets·Screener·Research·Chat

Stereotaxis, Inc. Common Stock (STXS) Financial Statements

Stereotaxis, Inc. Common Stock
SIC 3845 · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
FIGI BBG001SKC124
XASE · usd
1.32▲ 0.02 (1.54%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close1.30
Day's Range1.28 – 1.32
52-Week Range1.24 – 3.59
Volume586.2K
Avg Volume596.4K
Share Statistics
Shares Outstanding
Employees131
ExchangeXASE
Listed2004-08-12
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Stereotaxis, Inc. Common Stock (STXS)
What is Stereotaxis, Inc. Common Stock's Market Cap?
Stereotaxis, Inc. Common Stock's Market Cap is $132.3M, based on as-reported figures from SEC (XBRL) filings.
What is Stereotaxis, Inc. Common Stock's Price / Sales?
Stereotaxis, Inc. Common Stock's Price / Sales is 4.4×, based on as-reported figures from SEC (XBRL) filings.
What is Stereotaxis, Inc. Common Stock's Revenue (TTM)?
Stereotaxis, Inc. Common Stock's Revenue (TTM) is $30.1M, based on as-reported figures from SEC (XBRL) filings.
What is Stereotaxis, Inc. Common Stock's Net Income (TTM)?
Stereotaxis, Inc. Common Stock's Net Income (TTM) is -$23.6M, based on as-reported figures from SEC (XBRL) filings.
What is Stereotaxis, Inc. Common Stock's EBITDA?
Stereotaxis, Inc. Common Stock's EBITDA is -$21.2M, based on as-reported figures from SEC (XBRL) filings.
What is Stereotaxis, Inc. Common Stock's Diluted EPS (TTM)?
Stereotaxis, Inc. Common Stock's Diluted EPS (TTM) is -0.24, based on as-reported figures from SEC (XBRL) filings.
What is Stereotaxis, Inc. Common Stock's EBITDA Margin?
Stereotaxis, Inc. Common Stock's EBITDA Margin is -70.4%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Revenue
YoY growth-12.8%-15.8%+36.3%-18.8%
Cost of Revenue
Cost of Revenue
Gross margin
% of revenue58.5%60.3%50.1%54.9%
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Non-Operating Income (Expense)
Total operating expenses
% of revenue118.0%155.4%115.4%142.8%
Operating loss
% of revenue-59.6%-95.1%-65.4%-87.8%
Net Interest Income
Net loss
% of revenue-58.3%-93.2%-64.0%-86.6%
Cumulative dividend on convertible preferred stock
Net loss attributable to common stockholders
Earnings Per Share (Basic)
Earnings Per Share (Diluted)